Product Description
Mechanisms of Action: CYSLT1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Colombia | Dominican Republic | Japan | Korea | Peru | Turkey | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: ONO Pharm
Company Location: CHUO-KU OSAKA 541 JA M0
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Sinusitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ONO-1078-37 | P3 |
Completed |
Sinusitis |
2008-06-01 |